TIMP1 and lung cancer: With respect to these data, the findings of the present study using CM from cisplatin-treated lung cancer cells in the upper chamber favor the hypothesis that cisplatin acting via increased TIMP-1 release most likely confers interference with cellular motility rather than with chemoattraction of endothelial cells.